Geriatric Medicines - Global Market Outlook (2017-2026)

March 2018 | 191 pages | ID: GA4175A92C8EN
Stratistics Market Research Consulting

Abstracts

According to Stratistics MRC, the Global Geriatric Medicines Market is expected to grow at a CAGR of 9.3% during the forecast period. Increasing occurrence of diabetes and cardiovascular diseases amongst old people, increase in government support, improving healthcare infrastructure in number of upcoming economies are some of the key factors favouring the market growth. However, factors such as lack of awareness need of patient participation in clinical trials and side effects of medicines are hindering the market growth. In addition, increasing demand from emerging economies holds huge growth opportunities for market growth.

Geriatrics is a division of medicines connected to the remedial, clinical, social, and preventive aspects of ill health among old people over 65 years. The majority of the geriatrics is not capable to take their medication correctly at the intended time due to difficult in psychological and medical issues. The geriatric inhabitants need special attention and care for the rapid recovery of disorder or disease.

By Therapeutic Category, antihypertensive segment is projected to have significant share during the forecast period. Antihypertensive are a group of drugs that are used to treat hypertension (high blood pressure). Antihypertensive therapy prevents problems of high blood pressure such as stroke and myocardial infarction. Restless lifestyle of the urban populations and growing life expectancy are favouring the growth of antihypertensive medicines for geriatrics. By Geography, North America region is projected to grow at a significant rate due to high prevalence of chronic diseases, favourable administration initiative for the old people and presence of some pioneering companies of this market.

Some of the key players in geriatrics medicine market includes Abbott Laboratories, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc., Merck & Company Inc, Novartis AG, Pfizer and Inc., Sanofi S.A.

Therapeutic Categories Covered:

• Analgesic
• Antidiabetic
• Antihypertensive
• Antidepressant & Antipsychotic
• Proton Pump Inhibitor (PPI)
• Statins
• Other Therapeutic Categories

Conditions Covered:

• Arthritis
• Cancer
• Cardiovascular
• Neurological
• Osteoporosis
• Respiratory
• Other Conditions

Regions covered:

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• UK
• Italy
• France
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• New Zealand
• South Korea
• Rest of Asia Pacific
• South America
• Argentina
• Brazil
• Chile
• Rest of South America
• Middle East & Africa
• Saudi Arabia
• UAE
• Qatar
• South Africa
• Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions

3 MARKET TREND ANALYSIS

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.7 Emerging Markets
3.8 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 GLOBAL GERIATRIC MEDICINES MARKET, BY THERAPEUTIC CATEGORY

5.1 Introduction
5.2 Analgesic
5.3 Antidiabetic
5.4 Antihypertensive
5.5 Antidepressant & Antipsychotic
5.6 Proton Pump Inhibitor (PPI)
5.7 Statins
5.8 Other Therapeutic Categories

6 GLOBAL GERIATRIC MEDICINES MARKET, BY CONDITION

6.1 Introduction
6.2 Arthritis
6.3 Cancer
6.4 Cardiovascular
6.5 Neurological
6.6 Osteoporosis
6.7 Respiratory
6.8 Other Conditions

7 GLOBAL GERIATRIC MEDICINES MARKET, BY GEOGRAPHY

7.1 Introduction
7.2 North America
  7.2.1 US
  7.2.2 Canada
  7.2.3 Mexico
7.3 Europe
  7.3.1 Germany
  7.3.2 UK
  7.3.3 Italy
  7.3.4 France
  7.3.5 Spain
  7.3.6 Rest of Europe
7.4 Asia Pacific
  7.4.1 Japan
  7.4.2 China
  7.4.3 India
  7.4.4 Australia
  7.4.5 New Zealand
  7.4.6 South Korea
  7.4.7 Rest of Asia Pacific
7.5 South America
  7.5.1 Argentina
  7.5.2 Brazil
  7.5.3 Chile
  7.5.4 Rest of South America
7.6 Middle East & Africa
  7.6.1 Saudi Arabia
  7.6.2 UAE
  7.6.3 Qatar
  7.6.4 South Africa
  7.6.5 Rest of Middle East & Africa

8 KEY DEVELOPMENTS

8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 COMPANY PROFILING

9.1 Abbott Laboratories, Inc.
9.2 AstraZeneca plc
9.3 Boehringer Ingelheim GmbH
9.4 Bristol-Myers Squibb Company
9.5 Eli Lilly and Company
9.6 GlaxoSmithKline Plc.
9.7 Merck & Company Inc
9.8 Novartis AG
9.9 Pfizer, Inc.
9.10 Sanofi S.A

List Of Tables

LIST OF TABLES

Table 1 Global Geriatric Medicines Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Geriatric Medicines Market Outlook, By Therapeutic Category (2016-2026) (US $MN)
Table 3 Global Geriatric Medicines Market Outlook, By Analgesic (2016-2026) (US $MN)
Table 4 Global Geriatric Medicines Market Outlook, By Antidiabetic (2016-2026) (US $MN)
Table 5 Global Geriatric Medicines Market Outlook, By Antihypertensive (2016-2026) (US $MN)
Table 6 Global Geriatric Medicines Market Outlook, By Antidepressant & Antipsychotic (2016-2026) (US $MN)
Table 7 Global Geriatric Medicines Market Outlook, By Proton Pump Inhibitor (PPI) (2016-2026) (US $MN)
Table 8 Global Geriatric Medicines Market Outlook, By Statins (2016-2026) (US $MN)
Table 9 Global Geriatric Medicines Market Outlook, By Other Therapeutic Categories (2016-2026) (US $MN)
Table 10 Global Geriatric Medicines Market Outlook, By Condition (2016-2026) (US $MN)
Table 11 Global Geriatric Medicines Market Outlook, By Arthritis (2016-2026) (US $MN)
Table 12 Global Geriatric Medicines Market Outlook, By Cancer (2016-2026) (US $MN)
Table 13 Global Geriatric Medicines Market Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 14 Global Geriatric Medicines Market Outlook, By Neurological (2016-2026) (US $MN)
Table 15 Global Geriatric Medicines Market Outlook, By Osteoporosis (2016-2026) (US $MN)
Table 16 Global Geriatric Medicines Market Outlook, By Respiratory (2016-2026) (US $MN)
Table 17 Global Geriatric Medicines Market Outlook, By Other Conditions (2016-2026) (US $MN)
Table 18 North America Geriatric Medicines Market Outlook, By Country (2016-2026) (US $MN)
Table 19 North America Geriatric Medicines Market Outlook, By Therapeutic Category (2016-2026) (US $MN)
Table 20 North America Geriatric Medicines Market Outlook, By Analgesic (2016-2026) (US $MN)
Table 21 North America Geriatric Medicines Market Outlook, By Antidiabetic (2016-2026) (US $MN)
Table 22 North America Geriatric Medicines Market Outlook, By Antihypertensive (2016-2026) (US $MN)
Table 23 North America Geriatric Medicines Market Outlook, By Antidepressant & Antipsychotic (2016-2026) (US $MN)
Table 24 North America Geriatric Medicines Market Outlook, By Proton Pump Inhibitor (PPI) (2016-2026) (US $MN)
Table 25 North America Geriatric Medicines Market Outlook, By Statins (2016-2026) (US $MN)
Table 26 North America Geriatric Medicines Market Outlook, By Other Therapeutic Categories (2016-2026) (US $MN)
Table 27 North America Geriatric Medicines Market Outlook, By Condition (2016-2026) (US $MN)
Table 28 North America Geriatric Medicines Market Outlook, By Arthritis (2016-2026) (US $MN)
Table 29 North America Geriatric Medicines Market Outlook, By Cancer (2016-2026) (US $MN)
Table 30 North America Geriatric Medicines Market Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 31 North America Geriatric Medicines Market Outlook, By Neurological (2016-2026) (US $MN)
Table 32 North America Geriatric Medicines Market Outlook, By Osteoporosis (2016-2026) (US $MN)
Table 33 North America Geriatric Medicines Market Outlook, By Respiratory (2016-2026) (US $MN)
Table 34 North America Geriatric Medicines Market Outlook, By Other Conditions (2016-2026) (US $MN)
Table 35 Europe Geriatric Medicines Market Outlook, By Country (2016-2026) (US $MN)
Table 36 Europe Geriatric Medicines Market Outlook, By Therapeutic Category (2016-2026) (US $MN)
Table 37 Europe Geriatric Medicines Market Outlook, By Analgesic (2016-2026) (US $MN)
Table 38 Europe Geriatric Medicines Market Outlook, By Antidiabetic (2016-2026) (US $MN)
Table 39 Europe Geriatric Medicines Market Outlook, By Antihypertensive (2016-2026) (US $MN)
Table 40 Europe Geriatric Medicines Market Outlook, By Antidepressant & Antipsychotic (2016-2026) (US $MN)
Table 41 Europe Geriatric Medicines Market Outlook, By Proton Pump Inhibitor (PPI) (2016-2026) (US $MN)
Table 42 Europe Geriatric Medicines Market Outlook, By Statins (2016-2026) (US $MN)
Table 43 Europe Geriatric Medicines Market Outlook, By Other Therapeutic Categories (2016-2026) (US $MN)
Table 44 Europe Geriatric Medicines Market Outlook, By Condition (2016-2026) (US $MN)
Table 45 Europe Geriatric Medicines Market Outlook, By Arthritis (2016-2026) (US $MN)
Table 46 Europe Geriatric Medicines Market Outlook, By Cancer (2016-2026) (US $MN)
Table 47 Europe Geriatric Medicines Market Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 48 Europe Geriatric Medicines Market Outlook, By Neurological (2016-2026) (US $MN)
Table 49 Europe Geriatric Medicines Market Outlook, By Osteoporosis (2016-2026) (US $MN)
Table 50 Europe Geriatric Medicines Market Outlook, By Respiratory (2016-2026) (US $MN)
Table 51 Europe Geriatric Medicines Market Outlook, By Other Conditions (2016-2026) (US $MN)
Table 52 Asia Pacific Geriatric Medicines Market Outlook, By Country (2016-2026) (US $MN)
Table 53 Asia Pacific Geriatric Medicines Market Outlook, By Therapeutic Category (2016-2026) (US $MN)
Table 54 Asia Pacific Geriatric Medicines Market Outlook, By Analgesic (2016-2026) (US $MN)
Table 55 Asia Pacific Geriatric Medicines Market Outlook, By Antidiabetic (2016-2026) (US $MN)
Table 56 Asia Pacific Geriatric Medicines Market Outlook, By Antihypertensive (2016-2026) (US $MN)
Table 57 Asia Pacific Geriatric Medicines Market Outlook, By Antidepressant & Antipsychotic (2016-2026) (US $MN)
Table 58 Asia Pacific Geriatric Medicines Market Outlook, By Proton Pump Inhibitor (PPI) (2016-2026) (US $MN)
Table 59 Asia Pacific Geriatric Medicines Market Outlook, By Statins (2016-2026) (US $MN)
Table 60 Asia Pacific Geriatric Medicines Market Outlook, By Other Therapeutic Categories (2016-2026) (US $MN)
Table 61 Asia Pacific Geriatric Medicines Market Outlook, By Condition (2016-2026) (US $MN)
Table 62 Asia Pacific Geriatric Medicines Market Outlook, By Arthritis (2016-2026) (US $MN)
Table 63 Asia Pacific Geriatric Medicines Market Outlook, By Cancer (2016-2026) (US $MN)
Table 64 Asia Pacific Geriatric Medicines Market Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 65 Asia Pacific Geriatric Medicines Market Outlook, By Neurological (2016-2026) (US $MN)
Table 66 Asia Pacific Geriatric Medicines Market Outlook, By Osteoporosis (2016-2026) (US $MN)
Table 67 Asia Pacific Geriatric Medicines Market Outlook, By Respiratory (2016-2026) (US $MN)
Table 68 Asia Pacific Geriatric Medicines Market Outlook, By Other Conditions (2016-2026) (US $MN)
Table 69 South America Geriatric Medicines Market Outlook, By Country (2016-2026) (US $MN)
Table 70 South America Geriatric Medicines Market Outlook, By Therapeutic Category (2016-2026) (US $MN)
Table 71 South America Geriatric Medicines Market Outlook, By Analgesic (2016-2026) (US $MN)
Table 72 South America Geriatric Medicines Market Outlook, By Antidiabetic (2016-2026) (US $MN)
Table 73 South America Geriatric Medicines Market Outlook, By Antihypertensive (2016-2026) (US $MN)
Table 74 South America Geriatric Medicines Market Outlook, By Antidepressant & Antipsychotic (2016-2026) (US $MN)
Table 75 South America Geriatric Medicines Market Outlook, By Proton Pump Inhibitor (PPI) (2016-2026) (US $MN)
Table 76 South America Geriatric Medicines Market Outlook, By Statins (2016-2026) (US $MN)
Table 77 South America Geriatric Medicines Market Outlook, By Other Therapeutic Categories (2016-2026) (US $MN)
Table 78 South America Geriatric Medicines Market Outlook, By Condition (2016-2026) (US $MN)
Table 79 South America Geriatric Medicines Market Outlook, By Arthritis (2016-2026) (US $MN)
Table 80 South America Geriatric Medicines Market Outlook, By Cancer (2016-2026) (US $MN)
Table 81 South America Geriatric Medicines Market Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 82 South America Geriatric Medicines Market Outlook, By Neurological (2016-2026) (US $MN)
Table 83 South America Geriatric Medicines Market Outlook, By Osteoporosis (2016-2026) (US $MN)
Table 84 South America Geriatric Medicines Market Outlook, By Respiratory (2016-2026) (US $MN)
Table 85 South America Geriatric Medicines Market Outlook, By Other Conditions (2016-2026) (US $MN)
Table 86 Middle East & Africa Geriatric Medicines Market Outlook, By Country (2016-2026) (US $MN)
Table 87 Middle East & Africa Geriatric Medicines Market Outlook, By Therapeutic Category (2016-2026) (US $MN)
Table 88 Middle East & Africa Geriatric Medicines Market Outlook, By Analgesic (2016-2026) (US $MN)
Table 89 Middle East & Africa Geriatric Medicines Market Outlook, By Antidiabetic (2016-2026) (US $MN)
Table 90 Middle East & Africa Geriatric Medicines Market Outlook, By Antihypertensive (2016-2026) (US $MN)
Table 91 Middle East & Africa Geriatric Medicines Market Outlook, By Antidepressant & Antipsychotic (2016-2026) (US $MN)
Table 92 Middle East & Africa Geriatric Medicines Market Outlook, By Proton Pump Inhibitor (PPI) (2016-2026) (US $MN)
Table 93 Middle East & Africa Geriatric Medicines Market Outlook, By Statins (2016-2026) (US $MN)
Table 94 Middle East & Africa Geriatric Medicines Market Outlook, By Other Therapeutic Categories (2016-2026) (US $MN)
Table 95 Middle East & Africa Geriatric Medicines Market Outlook, By Condition (2016-2026) (US $MN)
Table 96 Middle East & Africa Geriatric Medicines Market Outlook, By Arthritis (2016-2026) (US $MN)
Table 97 Middle East & Africa Geriatric Medicines Market Outlook, By Cancer (2016-2026) (US $MN)
Table 98 Middle East & Africa Geriatric Medicines Market Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 99 Middle East & Africa Geriatric Medicines Market Outlook, By Neurological (2016-2026) (US $MN)
Table 100 Middle East & Africa Geriatric Medicines Market Outlook, By Osteoporosis (2016-2026) (US $MN)
Table 101 Middle East & Africa Geriatric Medicines Market Outlook, By Respiratory (2016-2026) (US $MN)
Table 102 Middle East & Africa Geriatric Medicines Market Outlook, By Other Conditions (2016-2026) (US $MN)